We are live on ! Find out more
TGI

TRV GP III Portfolio holdings

AUM $6.14M
1-Year Est. Return 45.44%
This Fund
S&P 500
This Quarter Est. Return
-23.61%
1 Year Est. Return
+45.44%
3 Year Est. Return
+169.98%
5 Year Est. Return
+802.39%
10 Year Est. Return
–
AUM
$573M
AUM Growth
-$218M
Cap. Flow
-$31.9M
Cap. Flow %
-5.56%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
NRIX icon
Nurix Therapeutics
NRIX
+$31.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$42.1B
$175M 30.61%
5,524,031
– –
PLRX icon
2
Pliant Therapeutics
PLRX
$65M
$170M 29.69%
5,839,160
– –
NRIX icon
3
Nurix Therapeutics
NRIX
$2.62B
$90.8M 15.85%
3,422,549
-1,085,784
-24% -$31.9M
FULC icon
4
Fulcrum Therapeutics
FULC
$288M
$62.5M 10.91%
5,962,202
– –
DBTX
5
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$27M 4.71%
3,139,685
– –
VYGR icon
6
Voyager Therapeutics
VYGR
$189M
$26.4M 4.61%
6,391,176
– –
JNCE
7
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$20.7M 3.62%
3,048,780
– –

Similar funds

TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

TRV GP III's Q2 2021 Portfolio in Review

As of Q2 2021, TRV GP III held 7 positions worth $573M, down 28% from $791M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP III withdrew a net $31.9M in Q2 2021, reducing 1 holding. Its largest reduction was Nurix Therapeutics, cutting an estimated $31.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP III's biggest Q2 2021 reduction was Nurix Therapeutics, cutting an estimated $31.9M.
  • TRV GP III's ten largest holdings make up 100% of its $573M portfolio in Q2 2021.
  • TRV GP III opened 0 new positions and closed 0 in Q2 2021.
  • TRV GP III's portfolio value fell 28% quarter-over-quarter to $573M.

Based on TRV GP III's 13F filing for Q2 2021, filed 11 Aug 2021.